Table 3– Studies in which exposure status was a predictor of test positivity (either test) in multivariate analysis
First author [ref.]Country (IGRA used)ParticipantsBCG vaccinees n/N (%)IGRA positives/total tested n/NIGRA OR (95% CI)TST positives/total tested n/N (%)TST OR (95% CI)Statistical agreement between IGRA(s) and TST κ (95% CI#)
Bartalesi 50Italy (QFT-G-IT)LTBI screening in 398 IMID subjects16/393 (4.1)52/3985.3 (1–28)75/323 (23.2)6.5 (1.1–36.9)0.55 (0.44–0.66)
Casas 53Spain (T-SPOT®.TB and QFT-G-IT)147 HCWs23/147 (15.6)T-SPOT.TB: 57/157; QFT-G-IT: 43/147T-SPOT: 2.1 (1.5–4.1); QFT: 1.82 (0.88–3.8)103/147 (70.1)0.94+ (0.46–1.93)T-SPOT.TB: 0.32 (se 0.061), BCG: 0.17 (se 0.09); QFT-G-IT: κ (total): 0.29 (se 0.052), BCG: 0.085 (se 0.05)
Hesseling 61South Africa (T-SPOT®.TB and QFT-G-IT)82 close contacts (29 children and 53 adults)62/82 (75.6)29/74T-SPOT.TB: 38.40 (7.59–616.11); QFT-G-IT: 14.94 (4.02–55.58)54/78 (69.2)3.83 (1.05–14.03)T-SPOT.TB: 0.12 (0.11–0.36); QFT-G-IT: 0.45 (0.28–0.62)
Laffitte 64Switzerland (T-SPOT®.TB)LTBI screening in 50 psoriasis patients before anti-TNF-α therapy46/50 (92.8)10/50Contact history: 5.67 (1.25–25.7); lesions on CXR: 25.3 (2.41–267)20/50 (40.0)Cutoff >5 mm: 2.14+ (0.55–8.3); >10 mm: 1.67+ (0.43–6.5)0.33 (sd 0.13)
Lien 65Vietnam (QFT-G-IT)300 HCWsLess than one-third (data not shown)142/3001.94 (1.04–3.64)176/288 (61.1)Not calculated0.44 (se 0.06), BCG: 0.29 (se 0.09)
Matulis 67Switzerland (QFT-G-IT)LTBI screening in 142 rheumatic patients118/142 (83.1)17/142Contact history: 17.8 (2.06–154); lesions in CXR: 66.8 (10.1–441);46/115 (40.0)6.23 (1.18–33.01)0.17 (0.02–0.32)
Seyhan 72Turkey (QFT-G-IT)LTBI screening in 100 haemodialysis patients72/100 (72.0)43/100Contact history: 5.08 (1.2–21.2); lesions in CXR: 3.06 (2.1–11.9)34/100 (34.0)Not calculated0.26, BCG: 0.15
Triverio 74Switzerland (T-SPOT®.TB and QFT-G-IT)LTBI screening in 62 ESRD patients14/62 (22.6)T-SPOT®.TB: 18/62; QFT-G-IT: 13/62T-SPOT®.TB: 1.2 (0.3–4.8; QFT-G-IT: 4.6 (1.2–18.1)12/62 (19.4)1.4+ (0.3–7.0)QFT-G-IT: 0.16; T-SPOT®-TB: 0.32
Vinton 77Australia (QFT-G-IT)LTBI screening in 481 hospital staff members from 5 hospitals375/481 (78.0)32/3815.6 (1.42–22.0)120/364 (33.0)1.96+ (0.68–5.63)0.16
Zellweger 48Switzerland (T-SPOT®.TB)91 contact persons (residents/staff members) in an institution for alcoholic patients78/91 (85.7)15/915.0 (1.05–23.86)40/91 (44.0)1.85+ (0.78–4.36)0.232
  • IGRA: interferon-γ release assay; BCG: bacille Calmette–Guérin; TST: tuberculin skin test; QGT-G-IT: QuantiFERON®-TB Gold In-Tube assay; LTBI: latent Mycobacterium tuberculosis infection; IMID: immunomediated inflammatory diseases; HCW: healthcare worker; TNF: tumour necrosis factor; CXR: chest radiography: ESRD: end-stage renal disease. #: unless otherwise stated; : no division into subgroups; +: not statistically significant.